臺灣博碩士論文加值系統

　　由於電漿表面改質方式，可改善物質的表面性質但保留基質原先的物性。且含有磷原子的官能基，亦會改變生醫材料的血液相容性。合併上述二項優點，本研究便以電漿聚合表面改質的方式，來將含有磷原子及氧原子之官能基接枝到基材上，其所選擇的單體分別為Trimethylphosphite (CH3O)3P和Triisopropylphosphite [(CH3)2CHO]3P，基材為蓋玻片，探討電漿聚合時，單體的蒸氣量、電漿功率、電漿聚合時間等因素，與材料表面性質的關係和影響。藉ATR - FTIR、ESCA、SEM、Contact angle，來分析各種電漿聚合條件所形成薄膜之表面性質。由ATR - FTIR，電漿聚合形成的膜皆具有含磷官能基；而ESCA，初步得知當單體為Triisopropylphosphite，操作條件400mtorr、20W、20min及單體為Triisopropylphosphite，條件250mtorr、20W、10min可形成較完整的膜。進一步由SEM及Contact angle的量測及由血液相容性的測試，發現在單體蒸氣量低或功率不夠大或反應時間短時，則膜呈現不連續膜狀；若功率過大或聚合時間增長時，可發現膜將破裂而有孔洞及裂痕產生。當單體為Trimethylphosphite，處理條件在400mtorr、20W、20min和單體為Triisopropylphosphite，條件250mtorr、20W、10min可形成完整膜，且接觸角分別只有6.3°與8.5°，而吸附在膜上的血小板數量很少也沒有聚集產生且幾乎沒有被活化。由此證明當單體為Triisopropylphosphite，操作條件400mtorr、20W、20min，及單體為Trimethylphosphite，條件250mtorr、20W、10min，可得到一均勻、完整無孔隙的薄膜、且膜表面具有含磷的官能基，而在血液相容性方面能改善血小板的吸附情形。
　　為了更進一步改善生醫材料的血液相容性，便以電漿共聚合的方式，將其他形式的官能基導入具有含磷官能基的材料上。實驗中，選擇Triisopropylphosphite和Dimethyisulfate（(CH3O)2SO2）兩種單體來產生電漿共聚合反應，基材仍為蓋玻片，其探討的方式與表面分析的方法同前所述。在實驗系統裡，固定單體Triisopropylphosphite蒸氣量，使壓力為250mtorr，控制功率為20W，反應10min，而漸漸增加單體Dimethyisulfate蒸氣量，來產生電漿共聚合反應，使產物同時具有含磷官能基和含硫官能基。當壓力增至310mtorr時，所得到的完整膜最為平滑，其親水性最好（約4.7°），且膜表面上血小板的吸附量較上一個實驗明顯減少較多。

　　Plasma surface modification has been shown to modify the surface properties without altering the physical properties of teh substrates. Meanwhile, sev eral studies have indicated the blood interactions with the artificial surfaces were altered with the addition of phosphorus - containing functionalities on the surface. Henceforth, plasma surface modification using trimethylphosphite. Henceforth, plasma surface modification using trimethylphosphite ((CH3O)3P) or triisopropylphosphite ((CH3)2CHO)3P) as the monomer source were investigated with an aim to improve the blood compatbility of the substrate, cover glass. Various surface characterization techniques, such as ATR - FTIR, ESCA, SEM and contact angle measurement, were carried out to evaluate the surface properties of the films formed under different processing conditions (e. g. plasma pressure, RF power, treatmetn time duration, monomer mass flow rate etc.). ATR - FTR and ESCA results indicated phosphorus - containing functionalities, such as phosphate or phosphite, were formed at all plasma polymers studied. In addition, ESCA and SEM results have shown a smooth, continuous plasma polymerized thin film was formed at 400 mtorr, 20 watts and 20 minutes treatment conditions for trimethylphosphite, and at 250 mtorr, 20 watts and 10 minutes for triisopropylphosphite. Films formed at lower pressure, lower power, shorter treatment duration were discontinuous. The smooth plasma polymerized thin films were damaged while the RF power or treatment time was further increased than the optimum film formation condition. Contact angle measurement indicated the contact angle values of these thin films at the optimum film formation conditions were 6.3° and 8.5° for the plasma polymerized trimethylphosphite and plasma polymerized trissopropylphosphite, respectively. In vitro platelet adhesion studies showed less platelet adhesion, less platelet aggregation and less platelet activation on the thin films created at the optimum film formation conditions than on the cover glass control and others formed at different plasma processing conditions.
　　Furthermore, plasma copolymerization of trissopropylphosphite and dimethylsulfate ( (CH3O)2SO2), suing cover glass as the substrate, was studied in order to incorporate both phosphorous - containgin and sulfur - contaning functionalities onto the thin film surface. An optimum film formation condition was found at 310 mtorr, 20 watts and 10 minutes plasma treatment duration while the mass flow rate of trisopropylphosphite was fixed at the rate which made the process pressure reading 250 mtorr initially. Contact angle value of this thin film is only 4.7°, which is more hydrophilic than the plasma polymerized triisopropylphosphite thin film. In yitro platelet adhesion studies have shown this plasma copolymerized thin film is more platelet compatible than either plasma polymerized triisopropylphosphite or trimethylphosphite thin films.